Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II multi-center open-label proof of concept study, consisting of two parts.
Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of the
combination regimen of dacomitinib plus PD-0325901 in patients with advanced KRAS mutant
(KRASm) non-small cell lung cancer (NSCLC). Part B is designed to perform a randomized
comparison of the combination of dacomitinib and PD-0325901 versus standard of care therapy
in patients with advanced KRASm NSCLC. It is hypothesized that with this combination strategy
the progression free survival of patients with KRASm NSCLC will be doubled.